{"protocolSection":{"identificationModule":{"nctId":"NCT01561430","orgStudyIdInfo":{"id":"13735"},"secondaryIdInfos":[{"id":"I4O-MC-BACC","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"2011-005217-37","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease","officialTitle":"Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease"},"statusModule":{"statusVerifiedDate":"2018-05","overallStatus":"TERMINATED","whyStopped":"Study terminated due to abnormal liver biochemical tests in some participants.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-03"},"primaryCompletionDateStruct":{"date":"2013-08","type":"ACTUAL"},"completionDateStruct":{"date":"2013-08","type":"ACTUAL"},"studyFirstSubmitDate":"2012-03-21","studyFirstSubmitQcDate":"2012-03-21","studyFirstPostDateStruct":{"date":"2012-03-23","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-03-24","resultsFirstSubmitQcDate":"2018-05-16","resultsFirstPostDateStruct":{"date":"2018-05-18","type":"ACTUAL"},"dispFirstSubmitDate":"2014-01-07","dispFirstSubmitQcDate":"2014-01-07","dispFirstPostDateStruct":{"date":"2014-02-06","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-05-16","lastUpdatePostDateStruct":{"date":"2018-05-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test positive for amyloid plaque."},"conditionsModule":{"conditions":["Alzheimer's Disease"],"keywords":["beta-secretase inhibitor"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":70,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"15 mg LY2886721","type":"EXPERIMENTAL","description":"LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks.","interventionNames":["Drug: LY2886721"]},{"label":"35 mg LY2886721","type":"EXPERIMENTAL","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks.","interventionNames":["Drug: LY2886721"]},{"label":"70 mg LY2886721","type":"EXPERIMENTAL","description":"LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks.","interventionNames":["Drug: LY2886721"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"LY2886721","armGroupLabels":["15 mg LY2886721","35 mg LY2886721","70 mg LY2886721"]},{"type":"DRUG","name":"Placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline to 12 Weeks in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations","description":"Percent change in lumbar CSF concentrations of Aβ1-40 and Aβ1-42 from baseline at 12 weeks post-dose was calculated. The units for CSF were picograms per milliliter (pg/mL). Least Squares (LS) means of percent change in concentration from baseline was calculated using analysis of covariance (ANCOVA) with baseline as a covariate and treatment as a fixed effect.","timeFrame":"Baseline, 12 weeks"},{"measure":"Change From Baseline to 26 Weeks in CSF Aβ1-40 and Aβ1-42 Concentrations","description":"Percent change in lumbar CSF concentrations of Aβ1-40 and Aβ1-42 from baseline at 26 weeks post-dose was to be calculated. The units for CSF were picograms per milliliter (pg/mL). LS means of percent change in concentration from baseline was calculated using ANCOVA with baseline as a covariate and treatment as a fixed effect.","timeFrame":"Baseline, 26 weeks"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Plasma Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations","description":"Percent change in plasma concentrations of Aβ1-40 and Aβ1-42 from baseline at 12 weeks and 26 weeks post-dose was calculated. The units for CSF were picograms per milliliter (pg/mL).","timeFrame":"Baseline, 12 weeks, 26 weeks"},{"measure":"Change From Baseline to 26 Weeks in Neuropsychological Test Battery (NTB)","description":"The NTB is a composite cognitive measure in clinical Alzheimer's disease studies and is a collection of several written and oral tests that examines verbal and nonverbal brain functions. NTB Z-score typically ranges from -3 to 3, with lower scores suggesting greater cognitive impairment. LS means were calculated using ANCOVA with baseline as a covariate and treatment as a fixed effect.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 26 Weeks in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)","description":"ADAS-Cog11 is an 11-item instrument measuring impairment in memory (Items 1-4, 7, 11), praxis (Items 4 and 5), orientation (Item 6), and language (Items 8-10). Item 1 ranged 0 (all items recalled correctly)-10 (none recalled correctly); Items 2-5 and 8-11 ranged 0 (all items named, performed, drawn, spoken, remember correctly/clearly)-5 (none correct/not clearly spoken); Item 6 ranged 0 (no incorrect responses)-8 (all incorrect); and Item 7 ranged 0 (all words remembered correctly)-12 (no words remembered correctly) for a total ADAS-Cog11 score of 0-70 with higher scores indicating greater disease severity. A score of 0-10 for delayed free recall and a conversion code of 0-5 for digit cancellation and maze completion was added to the total ADAS-Cog11 score for a total ADAS-Cog14 score ranging 0-90 with higher scores indicating greater impairment. LS means were calculated using Mixed Model Repeated Measures (MMRM) with Treatment + Visit + Treatment\\*Visit + Baseline + Baseline\\*Visit.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 26 Weeks in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)","description":"The CDR-SB is a composite measure of 6 domains of cognitive and functional performance: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Scores ranged from 0 to 18, with higher scores indicating greater impairment. LS means were calculated using MMRM with Treatment + Visit + Treatment\\*Visit + Baseline + Baseline\\*Visit.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 26 Weeks in Mini Mental State Examination (MMSE)","description":"The MMSE (Folstein et al. 1975) is one of the most widely used screening instruments for cognitive impairment. The test consists of five sections (orientation, registration, attention-calculation, recall, and language) and provides a total score ranging from 0 to 30, with lower scores indicative of greater cognitive impairment. LS means were calculated using MMRM with Treatment + Visit + Treatment\\*Visit + Baseline + Baseline\\*Visit.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline in Cerebrospinal Fluid (CSF) Tau and Phosphorylated Tau (Ptau)-181 Concentrations","description":"Percent change in lumbar CSF tau and ptau-181 concentrations from baseline at 12 weeks post-dose and 26 weeks post-dose was calculated. The units for CSF were picograms per milliliter (pg/mL). Least Squares (LS) means of percent change in concentration from baseline was calculated using analysis of covariance (ANCOVA) with baseline as a covariate and treatment as a fixed effect.","timeFrame":"Baseline, 12 weeks, 26 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nMeets criteria for MCI due to AD or Mild AD\n\nAll participants will be required to undergo assessment via the Mini Mental State Examination (MMSE) scale at screening\n\n* Participants with MMSE scores of 20 to 26, inclusive, may be enrolled provided they meet the criteria for mild AD, as follows:\n\n  * Participant meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD\n  * Clinical Dementia Rating Scale (CDR) score of 0.5 or 1\n  * Positive scan for the presence of amyloid beta\n* Participants with MMSE of 27 to 30, inclusive, may be enrolled as participants with MCI due to AD provided they meet the following criteria:\n\n  * Gradual and progressive change in memory function as reported by the participant or a caregiver during a period of more than 6 months\n  * Free and Cued Selective Reminding Test with Immediate Recall (FCSRT-IR): free recall ≤22 and total recall ≤46\n  * Absence of dementia\n  * Preservation of functional independence\n  * Exclusion of other potential (vascular, traumatic, or medical) causes of cognitive decline, where possible\n  * Positive scan for the presence of amyloid beta\n* Women must be postmenopausal\n* Men are required to use an approved barrier method of contraception if their partners are pregnant, or of childbearing potential and not using approved contraceptive methods\n\nExclusion Criteria:\n\n* Participant in another drug or device study\n* Have a history of frontotemporal dementia, Lewy body disease, vascular dementia, Huntington's disease, Parkinson's disease, progressive supranuclear palsy (PSNP), or other movement disorder\n* Participants are not on a stable standard of care (acetylcholinesterase inhibitors, memantine) initiated less than 2 months prior to entry or have less than 4 weeks of stable therapy. Note: Stable standard of care is allowed.\n* Have had a serious infectious disease affecting the brain in the past 5 years\n* Have had a serious or repeat head injury\n* Have significant retinal impairment or disease\n* Have had a stroke or other circulation problems that are affecting current health\n* Have had a seizure\n* Have major depressive disorder and are not on a stable dose of medication. Participants who no longer meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV) criteria for major depression may be included\n* History of schizophrenia, bipolar disorder, or severe mental illness\n* History of alcohol or drug abuse\n* Have asthma, chronic obstructive pulmonary disease (COPD), or other breathing disease that is not controlled with medicine\n* Have human immunodeficiency virus (HIV) or syphilis\n* Are taking blood thinners","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Phoenix","state":"Arizona","zip":"85006","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sun City","state":"Arizona","zip":"85351","country":"United States","geoPoint":{"lat":33.59754,"lon":-112.27182}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tucson","state":"Arizona","zip":"85741","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Long Beach","state":"California","zip":"90806","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"San Francisco","state":"California","zip":"94109","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Denver","state":"Colorado","zip":"80239","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New Haven","state":"Connecticut","zip":"06510","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Boca Raton","state":"Florida","zip":"33486","country":"United States","geoPoint":{"lat":26.3669,"lon":-80.13033}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Delray Beach","state":"Florida","zip":"33445","country":"United States","geoPoint":{"lat":26.46146,"lon":-80.07282}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fort Myers","state":"Florida","zip":"33912","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ocala","state":"Florida","zip":"34471","country":"United States","geoPoint":{"lat":29.1872,"lon":-82.14009}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"West Palm Beach","state":"Florida","zip":"33407","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Decatur","state":"Georgia","zip":"30033","country":"United States","geoPoint":{"lat":33.77483,"lon":-84.29631}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lexington","state":"Kentucky","zip":"40504","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Plymouth","state":"Massachusetts","zip":"02360","country":"United States","geoPoint":{"lat":41.95844,"lon":-70.66726}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Quincy","state":"Massachusetts","zip":"02169","country":"United States","geoPoint":{"lat":42.25288,"lon":-71.00227}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Monroe","state":"New Jersey","zip":"08831","country":"United States","geoPoint":{"lat":40.81288,"lon":-74.44238}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Albany","state":"New York","zip":"12206","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Durham","state":"North Carolina","zip":"27705","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dayton","state":"Ohio","zip":"45408","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Portland","state":"Oregon","zip":"97210","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Salt Lake City","state":"Utah","zip":"84106","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Biella","zip":"13900","country":"Italy","geoPoint":{"lat":45.56304,"lon":8.05796}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pisa","zip":"56126","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rome","zip":"00179","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Osaka","zip":"545-8586","country":"Japan","geoPoint":{"lat":34.69374,"lon":135.50218}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tokyo","zip":"113","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Amsterdam","zip":"1081 GM","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Barcelona","zip":"08014","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Getafe","zip":"28905","country":"Spain","geoPoint":{"lat":40.30571,"lon":-3.73295}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sant Cugal Del Valles","zip":"08195","country":"Spain"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"As a result of findings from the I4O-MC-BACJ study (NCT01534273), enrollment was discontinued to the 15 milligrams (mg) arm. The 9 participants already enrolled were allowed to continue study treatment at the 15 mg dose.","groups":[{"id":"FG000","title":"15 mg LY2886721","description":"LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks."},{"id":"FG001","title":"35 mg LY2886721","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"FG002","title":"70 mg LY2886721","description":"LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"FG003","title":"Placebo","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"20"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"20"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"7"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"13"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"12"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All enrolled participants.","groups":[{"id":"BG000","title":"15 mg LY2886721","description":"LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks."},{"id":"BG001","title":"35 mg LY2886721","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"BG002","title":"70 mg LY2886721","description":"LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"BG003","title":"Placebo","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"70"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.59","spread":"7.569"},{"groupId":"BG001","value":"72.50","spread":"8.378"},{"groupId":"BG002","value":"70.23","spread":"8.603"},{"groupId":"BG003","value":"67.73","spread":"7.126"},{"groupId":"BG004","value":"69.66","spread":"8.201"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"33"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"37"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"6"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"64"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"60"}]}]},{"title":"Netherlands","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"5"}]}]},{"title":"Japan","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to 12 Weeks in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations","description":"Percent change in lumbar CSF concentrations of Aβ1-40 and Aβ1-42 from baseline at 12 weeks post-dose was calculated. The units for CSF were picograms per milliliter (pg/mL). Least Squares (LS) means of percent change in concentration from baseline was calculated using analysis of covariance (ANCOVA) with baseline as a covariate and treatment as a fixed effect.","populationDescription":"All randomized participants with evaluable post-baseline CSF Aβ1-40 or Aβ1-42 data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percent change in Aβ1-40 and Aβ1-42","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"15 mg LY2886721","description":"LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks."},{"id":"OG001","title":"35 mg LY2886721","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG002","title":"70 mg LY2886721","description":"LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG003","title":"Placebo","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"12"}]}],"classes":[{"title":"Aβ1-40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-31.8","spread":"7.35"},{"groupId":"OG001","value":"-57.7","spread":"6.67"},{"groupId":"OG002","value":"-58.9","spread":"8.73"},{"groupId":"OG003","value":"3.7","spread":"5.96"}]}]},{"title":"Aβ1-42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-34.4","spread":"7.27"},{"groupId":"OG001","value":"-52.0","spread":"6.80"},{"groupId":"OG002","value":"-60.7","spread":"8.42"},{"groupId":"OG003","value":"6.5","spread":"6.06"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to 26 Weeks in CSF Aβ1-40 and Aβ1-42 Concentrations","description":"Percent change in lumbar CSF concentrations of Aβ1-40 and Aβ1-42 from baseline at 26 weeks post-dose was to be calculated. The units for CSF were picograms per milliliter (pg/mL). LS means of percent change in concentration from baseline was calculated using ANCOVA with baseline as a covariate and treatment as a fixed effect.","populationDescription":"Zero participants analyzed. CSF Aβ1-40 and Aβ1-42 concentrations data was not collected for analysis at 26 weeks.","reportingStatus":"POSTED","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"15 mg LY2886721","description":"LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks."},{"id":"OG001","title":"35 mg LY2886721","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG002","title":"70 mg LY2886721","description":"LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG003","title":"Placebo","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"type":"SECONDARY","title":"Change From Baseline in Plasma Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations","description":"Percent change in plasma concentrations of Aβ1-40 and Aβ1-42 from baseline at 12 weeks and 26 weeks post-dose was calculated. The units for CSF were picograms per milliliter (pg/mL).","populationDescription":"All randomized participants with evaluable post-baseline CSF Aβ1-40 or Aβ1-42 data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percent change in Aβ1-40 and Aβ1-42","timeFrame":"Baseline, 12 weeks, 26 weeks","groups":[{"id":"OG000","title":"15 mg LY2886721","description":"LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks."},{"id":"OG001","title":"35 mg LY2886721","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG002","title":"70 mg LY2886721","description":"LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG003","title":"Placebo","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}]}],"classes":[{"title":"Aβ1-40, Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-73.4","spread":"6.22"},{"groupId":"OG001","value":"-80.8","spread":"8.07"},{"groupId":"OG002","value":"-88.1","spread":"2.66"},{"groupId":"OG003","value":"1.90","spread":"15.0"}]}]},{"title":"Aβ1-40, Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-72.3","spread":"11.5"},{"groupId":"OG001","value":"-85.0","spread":"3.89"},{"groupId":"OG002","value":"-89.1","spread":"NA","comment":"Standard deviation not reported due to not enough participants for analyses."},{"groupId":"OG003","value":"0.944","spread":"22.6"}]}]},{"title":"Aβ1-42, Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-63.4","spread":"6.11"},{"groupId":"OG001","value":"-71.1","spread":"8.38"},{"groupId":"OG002","value":"-78.2","spread":"5.08"},{"groupId":"OG003","value":"0.541","spread":"10.1"}]}]},{"title":"Aβ1-42, Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-65.1","spread":"8.85"},{"groupId":"OG001","value":"-75.0","spread":"4.33"},{"groupId":"OG002","value":"-80.8","spread":"NA","comment":"Standard deviation not reported due to not enough participants for analyses."},{"groupId":"OG003","value":"1.82","spread":"9.98"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks in Neuropsychological Test Battery (NTB)","description":"The NTB is a composite cognitive measure in clinical Alzheimer's disease studies and is a collection of several written and oral tests that examines verbal and nonverbal brain functions. NTB Z-score typically ranges from -3 to 3, with lower scores suggesting greater cognitive impairment. LS means were calculated using ANCOVA with baseline as a covariate and treatment as a fixed effect.","populationDescription":"All randomized participants with evaluable NTB data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"15 mg LY2886721","description":"LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks."},{"id":"OG001","title":"35 mg LY2886721","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG002","title":"70 mg LY2886721","description":"LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG003","title":"Placebo","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.039","spread":"0.1096"},{"groupId":"OG001","value":"-0.161","spread":"0.1165"},{"groupId":"OG002","value":"0.424","spread":"0.3156"},{"groupId":"OG003","value":"-0.262","spread":"0.1028"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)","description":"ADAS-Cog11 is an 11-item instrument measuring impairment in memory (Items 1-4, 7, 11), praxis (Items 4 and 5), orientation (Item 6), and language (Items 8-10). Item 1 ranged 0 (all items recalled correctly)-10 (none recalled correctly); Items 2-5 and 8-11 ranged 0 (all items named, performed, drawn, spoken, remember correctly/clearly)-5 (none correct/not clearly spoken); Item 6 ranged 0 (no incorrect responses)-8 (all incorrect); and Item 7 ranged 0 (all words remembered correctly)-12 (no words remembered correctly) for a total ADAS-Cog11 score of 0-70 with higher scores indicating greater disease severity. A score of 0-10 for delayed free recall and a conversion code of 0-5 for digit cancellation and maze completion was added to the total ADAS-Cog11 score for a total ADAS-Cog14 score ranging 0-90 with higher scores indicating greater impairment. LS means were calculated using Mixed Model Repeated Measures (MMRM) with Treatment + Visit + Treatment\\*Visit + Baseline + Baseline\\*Visit.","populationDescription":"All randomized participants with evaluable ADAS-Cog data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"15 mg LY2886721","description":"LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks."},{"id":"OG001","title":"35 mg LY2886721","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG002","title":"70 mg LY2886721","description":"LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG003","title":"Placebo","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.77"},{"groupId":"OG001","value":"0.6","spread":"2.48"},{"groupId":"OG002","value":"0.6","spread":"7.41"},{"groupId":"OG003","value":"1.3","spread":"2.44"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)","description":"The CDR-SB is a composite measure of 6 domains of cognitive and functional performance: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Scores ranged from 0 to 18, with higher scores indicating greater impairment. LS means were calculated using MMRM with Treatment + Visit + Treatment\\*Visit + Baseline + Baseline\\*Visit.","populationDescription":"All randomized participants with evaluable CDR-SB data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"15 mg LY2886721","description":"LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks."},{"id":"OG001","title":"35 mg LY2886721","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG002","title":"70 mg LY2886721","description":"LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG003","title":"Placebo","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.432"},{"groupId":"OG001","value":"0.52","spread":"0.395"},{"groupId":"OG002","value":"1.50","spread":"1.013"},{"groupId":"OG003","value":"1.19","spread":"0.402"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks in Mini Mental State Examination (MMSE)","description":"The MMSE (Folstein et al. 1975) is one of the most widely used screening instruments for cognitive impairment. The test consists of five sections (orientation, registration, attention-calculation, recall, and language) and provides a total score ranging from 0 to 30, with lower scores indicative of greater cognitive impairment. LS means were calculated using MMRM with Treatment + Visit + Treatment\\*Visit + Baseline + Baseline\\*Visit.","populationDescription":"All randomized participants with evaluable MMSE data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"15 mg LY2886721","description":"LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks."},{"id":"OG001","title":"35 mg LY2886721","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG002","title":"70 mg LY2886721","description":"70 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG003","title":"Placebo","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.87"},{"groupId":"OG001","value":"-1.8","spread":"0.81"},{"groupId":"OG002","value":"0.2","spread":"2.41"},{"groupId":"OG003","value":"-3.0","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Cerebrospinal Fluid (CSF) Tau and Phosphorylated Tau (Ptau)-181 Concentrations","description":"Percent change in lumbar CSF tau and ptau-181 concentrations from baseline at 12 weeks post-dose and 26 weeks post-dose was calculated. The units for CSF were picograms per milliliter (pg/mL). Least Squares (LS) means of percent change in concentration from baseline was calculated using analysis of covariance (ANCOVA) with baseline as a covariate and treatment as a fixed effect.","populationDescription":"All randomized participants at 12 weeks with evaluable post-baseline CSF Tau or Ptau data.\n\nZero participants analyzed for 26 week CSF Tau or Ptau as data was not collected for analysis.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percent change in tau and ptau-181","timeFrame":"Baseline, 12 weeks, 26 weeks","groups":[{"id":"OG000","title":"15 mg LY2886721","description":"LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks."},{"id":"OG001","title":"35 mg LY2886721","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG002","title":"70 mg LY2886721","description":"LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks."},{"id":"OG003","title":"Placebo","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"12"}]}],"classes":[{"title":"CSF Tau, Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":"6.06"},{"groupId":"OG001","value":"2.6","spread":"5.42"},{"groupId":"OG002","value":"6.8","spread":"7.49"},{"groupId":"OG003","value":"-4.4","spread":"4.63"}]}]},{"title":"CSF Tau, Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"CSF Ptau, Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"4.81"},{"groupId":"OG001","value":"1.7","spread":"4.01"},{"groupId":"OG002","value":"4.3","spread":"5.41"},{"groupId":"OG003","value":"-3.6","spread":"3.40"}]}]},{"title":"CSF Ptau, Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","eventGroups":[{"id":"EG000","title":"15 mg LY2886721","description":"LY2886721: 15 mg, capsules, administered orally, once daily for 26 weeks.","seriousNumAffected":1,"seriousNumAtRisk":9,"otherNumAffected":8,"otherNumAtRisk":9},{"id":"EG001","title":"35 mg LY2886721","description":"LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks.","seriousNumAffected":2,"seriousNumAtRisk":23,"otherNumAffected":13,"otherNumAtRisk":23},{"id":"EG002","title":"70 mg LY2886721","description":"LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks.","seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":16,"otherNumAtRisk":18},{"id":"EG003","title":"Placebo","description":"Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks.","seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":15,"otherNumAtRisk":20}],"seriousEvents":[{"term":"Crohn's disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Cataract nuclear","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Diplopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Eye irritation","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Visual acuity reduced","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Abdominal tenderness","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Diverticulum intestinal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":20}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Gastritis erosive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":20}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Lip swelling","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Oesophageal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Alcohol poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Feeding tube complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Tooth fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Colour vision tests abnormal red-green","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Electrocardiogram change","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Liver function test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Increased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Joint range of motion decreased","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Muscle tightness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":20}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Squamous cell carcinoma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Apraxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Cerebral microhaemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Decreased vibratory sense","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Sinus headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":4,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Abnormal dreams","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Delusion","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Hallucination, visual","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Hypnopompic hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Initial insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Nightmare","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Obsessive thoughts","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Parasomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Restlessness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Sleep talking","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Stereotypy","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Terminal insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Cystitis interstitial","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Renal failure chronic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Actinic keratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Rash vesicular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Study was terminated early because of abnormal liver biochemical tests levels for 4 participants."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-07-25"},"conditionBrowseModule":{"meshes":[{"id":"D000544","term":"Alzheimer Disease"},{"id":"D060825","term":"Cognitive Dysfunction"}],"ancestors":[{"id":"D003704","term":"Dementia"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D024801","term":"Tauopathies"},{"id":"D019636","term":"Neurodegenerative Diseases"},{"id":"D019965","term":"Neurocognitive Disorders"},{"id":"D001523","term":"Mental Disorders"},{"id":"D003072","term":"Cognition Disorders"}],"browseLeaves":[{"id":"M29705","name":"Cognitive Dysfunction","asFound":"Mild Cognitive Impairment","relevance":"HIGH"},{"id":"M3885","name":"Alzheimer Disease","asFound":"Alzheimer's Disease","relevance":"HIGH"},{"id":"M6904","name":"Dementia","relevance":"LOW"},{"id":"M5204","name":"Brain Diseases","relevance":"LOW"},{"id":"M5742","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M23002","name":"Tauopathies","relevance":"LOW"},{"id":"M21558","name":"Neurodegenerative Diseases","relevance":"LOW"},{"id":"M21836","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M14473","name":"Psychotic Disorders","relevance":"LOW"},{"id":"M4815","name":"Mental Disorders","relevance":"LOW"},{"id":"M6301","name":"Cognition Disorders","relevance":"LOW"},{"id":"T2192","name":"Familial Alzheimer Disease","asFound":"Alzheimer's Disease","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":true}